National Institute of Mental Health

Five ways to combat growing polypharmacy among children
June 21, 2017By Tracey Walker
One expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.
Behavioral health top priority for employers
April 12, 2017By Tracey Walker
With a growing need for services, nearly nine in 10 employers cite behavioral health as an important priority in Willis Towers Watson survey.
Your New Role in the Battle Against Depression
Your New Role in the Battle Against Depression
March 15, 2017By Jill Sederstrom
A shortage of mental health-care providers, coupled with pharmacists’ unique skills and access to patients, has led to a significant opportunity for community and health-system pharmacists to aid in detection of depression and in medication selection and counseling for patients with depression.
Mental health: The secret sauce to healthcare reform
December 20, 2016By Tracey Walker
Mental health advocate Patrick J. Kennedy talks to Managed Healthcare Executive about reform, mental health equity, and how payers can help integrate care in mental health.
Severe irritability: Bipolar disorder or something else?
July 01, 2014By Kathryn Foxhall
Much has changed in research about children with irritability in recent years, notes Ellen Leibenluft, MD, chief of the Section on Bipolar Spectrum Disorders at the National Institute of Mental Health (NIMH).
New findings as to the origin of autism
April 03, 2014By Lisa Hack
Researchers have found areas of disruption in the brains of young children with autism spectrum disorder (ASD), indicating that ASD originates sometime early in the prenatal period, according to a new small explorative study.
Drugs in Perspective: Takeda's and Lundbeck’s Brintellix
January 09, 2014By Vy P. Pham PharmD, Adriana Alvidrez PharmD BCPS
Major depressive disorder (MDD) is a medical illness that is characterized by depressed mood, hopelessness, and loss of interest.1 According to the National Institute of Mental Health (NIMH), approximately 6.7% of US adult population experienced MDD, with 30.4% of these cases (2.0% of U.S. adult population) classified as severe.